Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2010

Pfenex to Supply Henry M. Jackson Foundation with Carrier Protein for Vaccine Development

  • Pefenex will supply cGMP-grade CRM197 carrier protein to The Henry M. Jackson Foundation (HJF) for the Advancement of Military Medicine to supply cGMP-grade CRM197 carrier protein. CRM197 is a nontoxic variant of diphtheria toxin and is utilized as a carrier protein in multiple approved conjugate vaccines.

    The arrangement will support testing and potential development of a conjugate vaccine. In addition, Pfenex will grant HJF access to a biologics master file that will be filed with the FDA to support regulatory submissions related to the vaccine.

    CRM197 has been shown to be an excellent carrier for polysaccharides and haptens and enables conversion of poorly immunogenic antigens to elicit an immunologic memory response. Pfenex has developed a recombinantly produced form and is making it available to vaccine developers at commercial scale quantities in both cGMP and reagent grades.

    “Along with our recently announced contract awarded by the U.S. Department of Health and Human Services/ Biomedical Advanced Research and Development Authority, in which Pfenex will develop a next-generation anthrax vaccine, this agreement demonstrates how Pfenex is leveraging our advanced protein-expression platform to support multiple areas of vaccine research and development in both complex antigen production and the supply of key conjugate vaccine carrier proteins.”

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »